Author

M. V. Ortiz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:differential expression· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

A. G. Henssen· 2 shared A. Eggert· 1 shared A. Kentsis· 1 shared A. L. Kung· 1 shared A. Letai· 1 shared A. Lissat· 1 shared A. M. Wengner· 1 shared A. Makohon-Moore· 1 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. G. Henssen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Subclonal somatic copy number alterations emerge and dominate in recurrent osteosarcoma

M. D. Kinnaman, S. Zaccaria, A. Makohon-Moore, B. Arnold, M. Levine, G. Gundem, J. E. A. Ossa, D. Glodzik, M. I. R. Sanchez, N. Bouvier, S. Li, E. Stockfisch, M. Dunigan, C. Cobbs, U. Bhanot, , C. A. Iacobuzio-Donahue

This study identifies subclonal copy number alterations in relapsed osteosarcoma, showing MYC gain/amplification in treatment-resistant clones and their emergence before chemotherapy.

bioRxiv · Jan 5, 2023 · PreprintCancer Biology

Exploiting a PAX3-FOXO1-induced synthetic lethal ATR dependency for rhabdomyosarcoma therapy

H. Dorado Garcia, Y. Bei, J. von Stebut, G. Ibanez, K. Imami, D. Gurgen, J. Rolff, K. Helmsauer, N. Timme, V. Bardinet, R. Chamorro Gonzalez, I. C. MacArthur, F. F. Pusch, C. Y. Chen, J. Schulz, , A. G. Henssen

This study identifies ATR as a synthetic lethal target in PAX3-FOXO1-driven rhabdomyosarcoma, showing ATR inhibition enhances PARP inhibitor efficacy and is tolerated in patients.

bioRxiv · Dec 4, 2020 · PreprintCancer Biology

Prohibitin is a prognostic marker of relapse and therapeutic target to block chemotherapy resistance in Wilms tumor

M. V. Ortiz, S. Ahmed, M. Burns, A. G. Henssen, T. Hollmann, I. MacArthur, S. Gunasekerea, L. Gaewsky, G. Bradwin, J. Ryan, A. Letai, Y. He, A. Naranjo, Y.-Y. Chi, M. LaQuaglia, , A. Kentsis

This study identifies prohibitin as a urine biomarker for Wilms tumor relapse and shows it promotes chemotherapy resistance by disrupting mitochondrial apoptosis.

bioRxiv · Dec 30, 2018Cancer Biology